Tag Archives: Comparative Effectiveness
Between 1980 and 2010, overall personal health care expenditures in the US grew nearly four-fold, driven in part by new technologies. What---if anything---should be done to regulate this innovation?
September 15, 2016
Four foundations are funding an effort to help sixteen schools of nursing to create innovative, robust, and sustainable interprofessional education programs. The intended outcome is more effective patient care in community-based settings.
July 28, 2016
Recently, we at Health Affairs hosted a Twitter chat with PCORI on the topic of patients' use of evidence. The chat was a follow-up to our "Patients' and Consumers' Use of Evidence" issue.
June 20, 2016
Spending on specialty medicines was responsible for 73 percent of overall medicine spending growth over the past five years. It's time to stop viewing high priced drugs as isolated incidents, but rather we should consider what we can do about it.
May 17, 2016
US law governing prescription pharmaceutical markets gives every new drug a long-term monopoly that prohibits competition. High prices and slow innovation cycles are the inevitable result and will remain so unless Congress makes fundamental changes in existing law.
October 29, 2015
Health care resources, no matter how represented, are ultimately finite. In spite of this, U.S. policymakers remain reluctant to engage in conversations that even hint at “rationing,” evidenced by the fact that PCORI is legislatively forbidden to include cost-effectiveness ratios in its...
September 1, 2015
How Institutional Review Boards Can Support Learning Health Systems While Providing Meaningful Oversight
IRBs should educate themselves about quality improvement and comparative effectiveness research, exempt studies that qualify for exemption, and provide waivers to informed consent, when that is appropriate.
June 5, 2015
The April issue of Health Affairs contains a cluster of papers focusing on the cost and quality of cancer care. Other subjects covered in the issue: health care payment reform; the diminished number of uninsured young adults; and regulatory approval of new drugs by the FDA. Publication of...
April 6, 2015
Incorporating Cost-Effectiveness Analysis Into Comparative-Effectiveness Research: The French Experience
Editor’s note: This post is part of a series of several posts related to the 4th European Forum on Health Policy and Management: Innovation & Implementation, held in Berlin, Germany on January 29 and 30, 2015. For updates on the Forum’s results please check the Center for Healthcare...
April 3, 2015
No one doubts that the US spends more than any other country on health care. Whether this higher spending produces commensurate health benefits, however, is far from certain. In the April 2012 issue of Health Affairs, Philipson et. al. make an intuitively persuasive observation, one which...
April 1, 2015